Indole Analogs as Novel Treatments for OCD

吲哚类似物作为强迫症的新疗法

• 批准号: 6443024
• 负责人: HOWARD P SARD
• 金额: $ 10.92万
• 依托单位: ORGANIX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6443024
• 关键词: 5 methoxy N,N dimethyltryptamine; drug design /synthesis /production; drug screening /evaluation; indoles; laboratory mouse; mental disorder chemotherapy; nonhuman therapy evaluation; obsessive compulsive disorder; psychopharmacology; receptor binding

DESCRIPTION (provided by applicant): Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited efficacy, can possess troubling side effects, and often require long-term treatment. Discovery of a new treatment for OCD would have considerable scientific value and commercial value. The hallucinogen psilocybin has shown preliminary efficacy against OCD, however even if further research on this compound is positive, FDA approval for psilocybin could be problematic. In Phase One we propose to synthesize carefully selected psilocybin analogs. The pharmacology of these compounds will be evaluated both in vitro and in vivo. From this project we specifically aim to discover one or more psilocybin analogs showing efficacy in an animal model for OCD comparable to that of the existing therapies. Such a result will strongly support continuation in Phase Two. The long-term goal of this project is to discover new, improved treatments for OCD. PROPOSED COMMERCIAL APPLICATION: Discovery of a novel, improved therapy for obsessive compulsive disorder could alleviate suffering for many people worldwide and would have very substantial commercial potential.

描述（由申请人提供）：强迫症（OCD）是 严重的精神疾病会影响全世界数百万人。 OCD现有疗法显示有限的功效，可能具有令人不安的一面 效果，通常需要长期治疗。发现新治疗 因为强迫症具有相当大的科学价值和商业价值。这 致幻蛋白酶蛋白酶已显示出针对强迫症的初步疗效，但是 即使对该化合物的进一步研究是积极的，FDA批准了 psilocybin可能是有问题的。在第一阶段，我们建议合成 精心选择的psilocybin类似物。这些化合物的药理学将 在体外和体内都可以评估。从这个项目中，我们特别针对 发现一个或多个psilocybin类似物显示在动物模型中的功效 对于与现有疗法相当的强迫症。这样的结果将 在第二阶段强烈支持继续。该项目的长期目标 是发现新的，改进的强迫症治疗方法。 拟议的商业应用：发现一种新颖的，改进的对强迫性疾病的治疗方法可以减轻全球许多人的痛苦，并且具有很大的商业潜力。